+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Insulin"

Diabetic Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Diabetic Ketoacidosis - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Ketoacidosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Anti-Diabetic Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Anti-Diabetic Drug Market - Forecasts from 2025 to 2030

  • Report
  • January 2025
  • 140 Pages
  • Global
From
human insulin market - Forecasts from 2025 to 2030 - Product Thumbnail Image

human insulin market - Forecasts from 2025 to 2030

  • Report
  • December 2024
  • 144 Pages
  • Global
From
Diabetic Peripheral Neuropathy- Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Peripheral Neuropathy- Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 80 Pages
  • Global
From
Diabetic Nephropathy - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Nephropathy - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 80 Pages
  • Global
From
Hypertriglyceridemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypertriglyceridemia - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 80 Pages
  • Global
From
Semaglutide Market Size, Emerging Insight, and Forecast to 2032 - Product Thumbnail Image

Semaglutide Market Size, Emerging Insight, and Forecast to 2032

  • Report
  • December 2024
  • 30 Pages
  • Global
From
Type 2 Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 240 Pages
  • Global
From
NLRP3 Protein Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

NLRP3 Protein Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 80 Pages
  • Global
From
From
From
From
Congenital Hyperinsulinism - Pipeline Insight, 2024 - Product Thumbnail Image

Congenital Hyperinsulinism - Pipeline Insight, 2024

  • Clinical Trials
  • July 2024
  • 60 Pages
  • Global
From
From
Hypoglycemia - Pipeline Insight, 2024 - Product Thumbnail Image

Hypoglycemia - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
Diabetic Retinopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Retinopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 210 Pages
  • Global
From
Insulin Resistance - Pipeline Insight, 2024 - Product Thumbnail Image

Insulin Resistance - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acromegaly - Pipeline Insight, 2024 - Product Thumbnail Image

Acromegaly - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Somatotropin deficiency - Pipeline Insight, 2024 - Product Thumbnail Image

Somatotropin deficiency - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Loading Indicator

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump. The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more